They summarized a large variety of STAT3 inhibitors which reverse cisplatin resistance in lung cancer, ovarian cancer, cervical cancer, breast cancer, laryngeal cancer, head and neck cancers, esophageal cancer, and hepatocellular carcinoma [52]. This evidence concerns the gene STAT3 and breast cancer.